Healthcare Equipment and Supplies
Company Overview of Veracyte, Inc.
Veracyte, Inc. operates as a molecular diagnostics company in the United States. It operates in the field of molecular cytology with genomic solutions that resolve diagnostic ambiguity and enable physicians to make informed treatment decisions at an early stage in patient care. The company offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers, which comprise the genomic tests for medullary thyroid cancer and BRAF V600E mutation status. It also develops a product to preoperatively identify idiopathic pulmonary fibrosis among patients presenting with a suspected interstitial lung disease; and the P...
7000 Shoreline Court
South San Francisco, CA 94080
Founded in 2006
Key Executives for Veracyte, Inc.
Co-Founder, Chief Executive Officer, President, Director and Member of Non-Management Equity Award Committee
Total Annual Compensation: $425.0K
Chief Financial Officer, Principal Accounting Officer and Member of Non-Management Equity Award Committee
Total Annual Compensation: $300.0K
Chief Operating Officer
Total Annual Compensation: $341.2K
Compensation as of Fiscal Year 2014.
Veracyte, Inc. Key Developments
Veracyte Seeks Acquisitions
Jun 24 15
Veracyte, Inc. (NasdaqGM:VCYT) has filed a Shelf Registration in the amount of $125.00 million, Veracyte will use the net proceeds from the sale of the securities offered by this prospectus for general corporate purposes. General corporate purposes may include additions to working capital, financing of capital expenditures, repayment or redemption of existing indebtedness, and future acquisitions and strategic investment opportunities.
Veracyte, Inc. Presents at William Blair’s 35th Annual Growth Stock Conference, Jun-09-2015 07:30 AM
Jun 5 15
Veracyte, Inc. Presents at William Blair’s 35th Annual Growth Stock Conference, Jun-09-2015 07:30 AM. Venue: Four Seasons Hotel, Chicago, Illinois, United States. Speakers: Bonnie H. Anderson, Co-Founder, Chief Executive Officer, President, Director and Member of Non-Management Equity Award Committee.
Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples
May 20 15
Veracyte, Inc. presented preliminary data demonstrating the ability of the company's molecular classifier to help distinguish idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases (ILDs) using samples obtained through bronchoscopy. The findings suggest the classifier's potential to help thousands of patients avoid invasive, risky and expensive surgery to resolve ambiguity in IPF diagnosis – a frequent challenge for physicians and patients. The data were presented at the American Thoracic Society (ATS) 2015 International Conference in Denver, Colo. The presentation coincides with online publication in TheLancet Respiratory Medicine of an article detailing foundational work and results from an independent test set, which demonstrated classifier performance using patient tissue samples obtained through surgery. The data shared at ATS demonstrate the ability of a Veracyte molecular classifier to distinguish the presence of a specific pathology pattern that is a hallmark of IPF among samples obtained through transbronchial bronchoscopy (TBB). This pathology pattern – whose presence is essential to IPF diagnosis – is often difficult to distinguish without surgery. Using whole-genome data and classifiers trained by histopathology "truth," researchers developed a classifier that could distinguish this pattern with high specificity (92 percent), suggesting its ability to identify and distinguish IPF from other ILDs, including non-specific interstitial pneumonia, emphysema and organizing pneumonia. Each year in the United States and Europe, up to 200,000 patients are suspected of having an ILD, including IPF, which is the most common and most deadly, and is difficult to diagnose.
Similar Private Companies By Industry
Recent Private Companies Transactions